NOWDiagnostics Launches at-Home Syphilis Test in the US

NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today released its First To Know Syphilis Test nationwide. 

First To Know is the only syphilis test in the U.S. with FDA marketing authorization for OTC use, and it can now be purchased online on Amazon and in major retail, pharmacy, and drugstore locations across the United States.

This first-of-its-kind, self-directed rapid test provides in-home results in 15 minutes with a drop of blood. It offers individuals an accurate, easy-to-use, and private way to test for syphilis.

“The First To Know Syphilis Test is designed to break down barriers to healthcare access and address the stigma that too often surrounds STI testing. By empowering individuals to test privately and conveniently, anytime and anywhere, we’re supporting public health initiatives focused on expanding access to testing and reducing the spread of syphilis,” said Rob Weigle, CEO of NOWDx. “Thanks to our retail and our Public Health partners, this test is now accessible across the country at an affordable price point—under $30, similar to or less than a typical co-pay—offering a meaningful solution for people who might otherwise delay or avoid testing and enabling them to take control of their health.”

“With syphilis cases at critical levels nationwide, accessible testing options like the First To Know Syphilis Test are more essential than ever,” said Harold Phillips, Deputy Director of Programs at the National Minority AIDS Council (NMAC) and Former Director of the White House Office of National AIDS Policy (ONAP). “For those at risk, including individuals with symptoms or exposure and especially pregnant women, having access to private, convenient testing can make all the difference. We’ve seen with the HIV epidemic that removing barriers to early testing is key to controlling the spread of infection and ensuring timely care, especially for communities disproportionately impacted. Expanding access to tools like this test represents a vital step toward a healthier, more equitable future.”